Literature DB >> 1828058

Differential effects of monophosphoryl lipid A on expression of suppressor T cell activity in lipopolysaccharide-responsive and lipopolysaccharide-defective strains of C3H mice.

F S Ekwunife1, C E Taylor, M B Fauntleroy, P W Stashak, P J Baker.   

Abstract

Lipopolysaccharide (LPS)-responsive and LPS-defective strains of C3H mice did not differ in the capacity to make an antibody response to type III pneumococcal polysaccharide or in the degree of thymus-derived suppressor cell (Ts) activity generated following exposure to type III pneumococcal polysaccharide. However, treatment with monophosphoryl lipid A (MPL) abolished the expression of Ts function in LPS-responsive but not LPS-defective mice. Since this effect was elicited by different preparations of MPL, it appears to be a general property of MPL mediated by direct action of MPL on activated Ts.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1828058      PMCID： PMC257987          DOI： 10.1128/iai.59.6.2192-2194.1991

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  20 in total

Review 1.  Regulation of magnitude of antibody response to bacterial polysaccharide antigens by thymus-derived lymphocytes.

Authors:  P J Baker
Journal:  Infect Immun       Date:  1990-11       Impact factor: 3.441

2.  Inactivation of suppressor T cell activity by the nontoxic lipopolysaccharide of Rhodopseudomonas sphaeroides.

Authors:  P J Baker; C E Taylor; P W Stashak; M B Fauntleroy; K Hasløv; N Qureshi; K Takayama
Journal:  Infect Immun       Date:  1990-09       Impact factor: 3.441

3.  Immunomodulatory activity of monophosphoryl lipid A in C3H/HeJ and C3H/HeSnJ mice.

Authors:  J R Hiernaux; P W Stashak; J L Cantrell; J A Rudbach; P J Baker
Journal:  Infect Immun       Date:  1989-05       Impact factor: 3.441

4.  Inactivation of suppressor T-cell activity by nontoxic monophosphoryl lipid A.

Authors:  P J Baker; J R Hiernaux; M B Fauntleroy; B Prescott; J L Cantrell; J A Rudbach
Journal:  Infect Immun       Date:  1988-05       Impact factor: 3.441

5.  Application of transformations to normalize the distribution of plaque-forming cells.

Authors:  C F Gottlieb
Journal:  J Immunol       Date:  1974-07       Impact factor: 5.422

6.  Direct evidence for the involvement of T suppressor cells in the expression of low-dose paralysis to type III pneumococcal polysaccharide.

Authors:  P J Baker; D F Amsbaugh; P W Stashak; G Caldes; B Prescott
Journal:  J Immunol       Date:  1982-03       Impact factor: 5.422

7.  Lipid A and immunotherapy.

Authors:  E Ribi; J L Cantrell; K Takayama; N Qureshi; J Peterson; H O Ribi
Journal:  Rev Infect Dis       Date:  1984 Jul-Aug

8.  Endotoxin-induced T lymphocyte proliferation.

Authors:  S N Vogel; M L Hilfiker; M J Caulfield
Journal:  J Immunol       Date:  1983-04       Impact factor: 5.422

9.  Enrichment of suppressor T cells by means of binding to monophosphoryl lipid A.

Authors:  P J Baker; K R Haslov; M B Fauntleroy; P W Stashak; K Myers; J T Ulrich
Journal:  Infect Immun       Date:  1990-03       Impact factor: 3.441

10.  Activation of antigen-specific suppressor T cells by B cells from mice immunized with type III pneumococcal polysaccharide.

Authors:  C E Taylor; P W Stashak; G Caldes; B Prescott; T E Chused; A Brooks; P J Baker
Journal:  J Exp Med       Date:  1983-09-01       Impact factor: 14.307
View more
  3 in total

1.  Differential sensitivity of CD8+ suppressor and cytotoxic T lymphocyte activity to bacterial monophosphoryl lipid A.

Authors:  F Esquivel; C E Taylor; P J Baker
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

2.  Structural features that influence the ability of lipid A and its analogs to abolish expression of suppressor T cell activity.

Authors:  P J Baker; T Hraba; C E Taylor; K R Myers; K Takayama; N Qureshi; P Stuetz; S Kusumoto; A Hasegawa
Journal:  Infect Immun       Date:  1992-07       Impact factor: 3.441

3.  Abrogation of suppression of delayed hypersensitivity induced by Candida albicans-derived mannan by treatment with monophosphoryl lipid A.

Authors:  J E Domer; L G Human; G B Andersen; J A Rudbach; G L Asherson
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.